Market Cap : 1 B | Enterprise Value : 933.74 M | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Myovant Sciences's Total Assets for the quarter that ended in Mar. 2022 was $520.0 Mil.
During the past 12 months, Myovant Sciences's average Total Assets Growth Rate was 114.00% per year. During the past 3 years, the average Total Assets Growth Rate was 71.90% per year. During the past 5 years, the average Total Assets Growth Rate was 73.50% per year.
During the past 7 years, Myovant Sciences's highest 3-Year average Total Assets Growth Rate was 80.90%. The lowest was 56.40%. And the median was 71.90%.
Total Assets is connected with ROA %. Myovant Sciences's annualized ROA % for the quarter that ended in Mar. 2022 was -42.18%. Total Assets is also linked to Revenue through Asset Turnover. Myovant Sciences's Asset Turnover for the quarter that ended in Mar. 2022 was 0.10.
The historical data trend for Myovant Sciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Myovant Sciences's Total Assets for the fiscal year that ended in Mar. 2022 is calculated as
Total Assets | = | Total Equity (A: Mar. 2022 ) | + | Total Liabilities (A: Mar. 2022 ) |
= | -473.477 | + | 993.488 | |
= | 520.0 |
Myovant Sciences's Total Assets for the quarter that ended in Mar. 2022 is calculated as
Total Assets | = | Total Equity (Q: Mar. 2022 ) | + | Total Liabilities (Q: Mar. 2022 ) |
= | -473.477 | + | 993.488 | |
= | 520.0 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Assets is connected with ROA %.
Myovant Sciences's annualized ROA % for the quarter that ended in Mar. 2022 is
ROA % | = | Net Income (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | -237.14 | / | ( (604.292 | + | 520.011) | / 2 ) | |
= | -237.14 | / | 562.1515 | ||||
= | -42.18 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Myovant Sciences's Asset Turnover for the quarter that ended in Mar. 2022 is
Asset Turnover | ||||||
= | Revenue (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | 57.567 | / | ( (604.292 | + | 520.011) | / 2 ) |
= | 57.567 | / | 562.1515 | |||
= | 0.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Myovant Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
From GuruFocus
Other Sources
By Zacks 2021-05-11
By Zacks 2021-05-10
By Zacks 2020-12-16
By Zacks 2021-07-01
By Zacks 2020-12-29
By Zacks 2021-09-10
By Seekingalpha 2021-07-28
By Seekingalpha 2021-01-19
By Seekingalpha 2022-01-02
By Zacks 2021-10-26
By Seekingalpha 2020-12-22
By Zacks 2021-03-25